Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., . . . Tam, C. S. (2021). Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia.
Citación estilo ChicagoWierda, William G., et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia. 2021.
Cita MLAWierda, William G., et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia. 2021.
Precaución: Estas citas no son 100% exactas.